COMMERCIALIZING WORLD-CLASS CANCER INNOVATION

Seeding and scaling Ontario’s premiere entrepreneurial ventures for patients and the economy.

ONTARIO RESEARCH Leveraging breakthrough innovation and community network COMMERCIALIZATION VENTURE Investing seed capital, creating & scaling start-ups, securing strategic partners PATIENT & ECONOMIC IMPACT Driving clinical trials, job creation, talent development, sustainable biotech in Ontario ONTARIO RESEARCH Leveraging breakthrough innovation and community network COMMERCIALIZATION VENTURE Investing seed capital, creating & scaling start-ups, securing strategic partners PATIENT & ECONOMIC IMPACT Driving clinical trials, job creation, talent development, sustainable biotech in Ontario

OUR IMPACT

Increasing the value of Ontario’s best oncology innovations and attracting investment from the private sector (current as of June 2022).

In total funding and equity investments

In additional financing attracted

Ontario start-ups created

First-in-human studies

PORTFOLIO

Our investments are at the forefront of Ontario’s biotech ecosystem.

FIND OUT MORE

FUNDS

Our investments bridge the life sciences seed funding gap.

FIND OUT MORE

KEY SUCCESSES

Our investments have resulted in significant partnerships, clinical trials, job creation and leveraged financing for the province.

RECENT NEWS

Keep up to date on our investments and business developments in recent news stories and summaries.

  • FACIT’s David O’Neill shares strategy for Ontario intellectual property

    June 16, 2022 – June 16, 2022 – The paper “How to boost Ontario’s life sciences IP to help patients and the economy” discusses the importance of seed-stage investing and commercialization-venture partnerships to reap the benefits of taxpayers’ investment in post-secondary education and health research.

    Read More from FACIT’s David O’Neill shares strategy for Ontario intellectual property

  • FACIT invests in OICR’s groundbreaking approaches to integrated drug discovery and cancer informatics

    April 28, 2022 – Early-stage capital positions science and intellectual property for Ontario economic impact April 27, 2022 – FACIT announced two recent strategic investments from its Prospects Oncology Fund in innovations arising from renowned cancer experts at the Ontario Institute for Cancer Research (OICR): Dr. Rima Al-awar, Head of Therapeutic Innovation and Drug Discovery, and Dr. Lincoln Stein, Head

    Read More from FACIT invests in OICR’s groundbreaking approaches to integrated drug discovery and cancer informatics

  • FACIT announces winner of 2022 Falcons’ Fortunes pitch competition on World Cancer Day

    February 4, 2022 – Annual event showcases emerging entrepreneurs and FACIT’s commitment to advance Ontario’s most promising oncology innovations February 4, 2022 – FACIT, a commercialization venture firm for Ontario cancer innovations, is pleased to announce the 2022 winner of its Falcons’ Fortunes pitch competition: Point Surgical Inc.. Point Surgical was founded as a joint venture between Toronto’s University Health

    Read More from FACIT announces winner of 2022 Falcons’ Fortunes pitch competition on World Cancer Day

We were established by the Ontario Institute for Cancer Research (OICR) to support commercialization, technology transfer, and development activities. OICR conducts and enables world-class cancer research, filling a critical role as a pan-provincial connector of oncology researchers, resources and cancer innovation development. Together with OICR, we drive a shared vision to attract more R&D investment in Ontario and help the best oncology innovations reach the market and save lives. 

FACIT is funded in part by the Government of Ontario through OICR